Printer Friendly

Editas Medicine names new director.

M2 EQUITYBITES-February 23, 2018-Editas Medicine names new director


Editas Medicine, a Genome editing company, has named Dr Jessica Hopfield as its director, it was reported yesterday.

Dr Hopfield will also serve on the board's audit committee. She has more than two decades of experience in the medical and healthcare fields and she has held management positions at Merck Sharp & Dohme in clinical development, outcomes research and marketing.

Dr Hopfield said: "I am honoured to join Editas Medicine's board of directors. Editas is on the forefront of a new era in medicine, and I look forward to working with the team and helping guide the company in the coming years."

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 23, 2018
Previous Article:US FDA accepts for filing Acorda Therapeutics' new drug application for Inbrija.
Next Article:Carenity names new business development director for Europe.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters